- RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Afimkibart for people with moderately to severely active Crohn's disease. It's a Phase 3 study, which means it's a big step before the medicine might become widely available, looking at how well it works and if it's safe.
For: Moderately to Severely Active Crohns DiseaseUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
This study is looking into a new medication called Afimkibart for adults with moderate to severe rheumatoid arthritis. It's for those who haven't found enough relief from or can't take other common treatments. The aim is to see how well it works and if it's safe.
For: Rheumatoid ArthritisUnited States · Argentina · Belgium - Active not recruitingPHASE2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
This study is testing a new medicine called Afimkibart for moderate to severe eczema in adults. Researchers want to see if it's safe and effective compared to a dummy treatment. It's a Phase 2 trial, meaning it's still early stage research.
For: Atopic DermatitisUnited States · Brazil · Canada - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine, Afimkibart, for people with moderate to severe Crohn's disease. We want to see if it helps reduce symptoms and if it's safe to use. Half the people will get the new medicine, and half will get a dummy medicine.
For: Moderately to Severely Active Crohns DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Afimkibart for children aged 2-17 with Crohn's disease that hasn't responded well to other treatments. It aims to see how well it works, if it's safe, and how the body handles it.
For: Moderately to Severely Active Crohns DiseaseUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for people aged 16-80 with ulcerative colitis that is moderately to severely active. It aims to see how well it works and if it's safe compared to a dummy drug. We hope it could be a new treatment option.
For: Moderately to Severely Active Ulcerative ColitisUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for children aged 2-17 with moderate to severe ulcerative colitis. It aims to see if the medication is safe, helps them feel better, and works well compared to a dummy treatment.
For: Moderately to Severely Active Ulcerative ColitisUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine called Afimkibart for people with moderate to severe ulcerative colitis. It aims to see how well it works and if it's safe compared to a dummy drug. The study is for adults aged 16 to 80 who haven't found existing treatments helpful.
For: Moderately to Severely Active Ulcerative ColitisUnited States · Argentina · Australia - RecruitingPHASE1
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
This study is looking at how a new medicine, Afimkibart, affects how your body processes other common medicines in people with active ulcerative colitis. We want to see if it changes how your body uses them.
For: Active Ulcerative ColitisUnited States · Belgium · Germany